Inscriere cercetatori

Daca aveti cont Ad Astra si de Facebook, intrati pe pagina de profil pentru a da dreptul sa va logati pe site doar cu acest buton.

Site nou !

Daca nu va puteti recupera parola (sau aveti alte probleme), scrieti-ne la pagina de contact. Situl vechi se gaseste la adresa


A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients

Domenii publicaţii > Ştiinţe medicale + Tipuri publicaţii > Articol în revistã ştiinţificã

Autori: Wildiers H, Jurcut R, Ganame J, Herbots L, Neven P, De Backer J, Denys H, Cocquyt V, Rademakers F, Voigt JU, Paridaens R.

Editorial: Crit Rev Oncol Hematol., 67(2), p.133-8, 2008.


In this pilot study, we examined the feasibility and toxicity in 16 elderly women aged >65 receiving six cycles of pegylated liposomal doxorubicin (PL-DOX) cyclophosphamide as adjuvant chemotherapy for breast cancer. An extensive cardiologic assessment was also performed including echocardiographic Doppler-based strain rate imaging (SRI), a promising new sensitive technique to assess cardiac function. All but one patient finished the six planned cycles without major dose reductions or delay, and with limited serious toxicity showing the feasibility of this regimen. Significant decreases in radial strain and strain rate were found after six cycles of treatment while left ventricle ejection fraction remained unchanged. SRI may be a useful tool in the follow-up of elderly patients treated with anthracyclines, allowing early initiation of preventive measures in order to prevent further irreversible cardiac damage.

Cuvinte cheie: Breast cancer; Pegylated liposomal doxorubicin; Cardiac effects; Doppler myocardial imaging; Elderly